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Abstract 
 
 MUTANT Ras ELEVATES DEPENDENCE ON SERUM LIPIDS AND CREATES A 
SYNTHETIC LETHALITY FOR RAPAMYCIN 
By Darin Salloum 
Adviser: Professor David A. Foster 
          Over past decade, metabolic alterations in cancer cells have received a substantial amount 
of interest. It had been established that cancer cells undergo a significant amount of metabolic 
alterations, and some of these alterations are similar to those in normal highly proliferative cells.  
However, it is becoming more apparent that many of the metabolic alterations are specific to 
particular oncogenic signaling pathways. Although altered metabolic machinery makes cancer 
cells more efficient at promoting growth when nutrients are supplied at the sufficient amounts, 
the dependency of cancer cells on particular metabolic reprogramming deems cancer cells 
susceptible to disruptions within metabolic network. Thus, the identification of metabolic 
weaknesses of cancer cells create a platform for therapeutic interventions. 
          The conversion of normal cells to cancer cells involves a shift from catabolic to anabolic 
metabolism involving increased glucose uptake and the diversion of glycolytic intermediates into 
nucleotides, amino acids and lipids needed for cell growth.  An underappreciated aspect of 
nutrient uptake is the utilization of serum lipids.  We investigated the dependence of human 
cancer cells on serum lipids and report here that Ras-driven human cancer cells are uniquely 
dependent on serum lipids for both proliferation and survival.  Moreover, Ras-driven cancer cells 
fail to adapt lipid metabolism upon lipid deprivation.  Removal of serum lipids also sensitizes 
v 
 
Ras-driven cancer cells to rapamycin.  Suppressing pinocytosis in Ras-driven cancer cells 
similarly created sensitivity to suppression of mTORC1 - the mammalian/mechanistic target of 
rapamycin.   
          The findings reported here reveal an enhanced need for serum lipids in Ras-driven human 
cancer cells that creates a synthetic lethal phenotype for suppressing mTORC1.  While depriving 
humans of serum lipids is not practical, suppressing uptake of lipids is possible and could be 
exploited therapeutically, presenting speculated that this property displayed by Ras-driven cancer 
cells represents an Achilles’ heel for the large number of human cancers that are driven by 
activating Ras mutations.   
          mTOR has long been known to respond to amino acids, glucose and energy. However, 
lipids are another essential nutrient, and sensing mechanism on sufficiency of lipid precursors is 
not yet known.  Based on the central position of PA in lipid biosynthesis, and its involvement in 
mTOR regulation, here we show that PA feeds into mTOR as a metabolite for sensing lipid 
precursors. In Ras-driven cells, PLD activity increase due to lipid withdrawal may be a 
mechanism to keep mTOR active during metabolic insufficiency stress. 
 
 
 
 
 
 
vi 
 
Acknowledgements 
 
          First of all, I would like to thank my mentor, Dr. David Foster, for his guidance throughout 
my graduate research.  Not only had he taught me to be a good scientist, but also trained to be an 
efficient thinker and good communicator. His ‘What do you want to say’ and ‘What this mean’ is 
a lesson that I will never forget and the method that shaped my way of doing science. I am 
thankful for his lesson of open communication and discussion that he led in the lab and that 
created my outlook of productive collaborative work. I am also thankful to the awesome group of 
people I worked with in the lab. They include Mahesh Saqcena, Suman Mukhodadhyay, Deepak 
Menon, Amrita Chaterjee, Matthew Utter, Paige Yellen, Limei Xui, Maria Frias and Deven 
Patel. I was also lucky to have the pleasure of working with two extraordinary students, 
Aleksandra Polonetskaya and Kaity Tung, who contributed tremendously to many aspects of my 
work.  
          I would like to thank Dr. Mitchell Goldfarb and Dr. Laurel Eckhardt who were beyond 
ordinary committee members. I am grateful for their way of leading onto the question and their 
patience that allowed me to develop deeper understanding of my research and science in general. 
I am honored to have Dr. Anant Menon and Dr. Gilbert Di Paolo to serve on my committee and 
grateful for their time and feedback on my work. I would like to thank Dr. Neal Rosen for his 
input and advice on my work.  
         I don’t believe that my work could have been done without support of our Department, 
including students and administrators within Biology Department, and the positive friendly 
environment that was present throughout the time of my work. 
vii 
 
          Finally, words alone cannot describe the gratitude I owe to my parents, Imad and Svetlana 
Salloum, and to my best siblings in the world, Alina and Issa, for their continuous support 
throughout all my academic achievements. I am grateful to my other two families, Basel and 
Effie and Ousama and Yvonne Salloum, for their unwavering encouragement throughout my 
school years, and help in all things small and large. I owe my family everything that I have done 
and everything that I am.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
Table of contents 
Abstract .......................................................................................................................................... iv 
Acknowledgements ........................................................................................................................ vi 
Table of contents .......................................................................................................................... viii 
List of abbreviations ...................................................................................................................... xi 
List of Figures and Tables ............................................................................................................. xii 
CHAPTER I .................................................................................................................................... 1 
INTRODUCTION .......................................................................................................................... 1 
1.1. CANCER. HALLMARKS OF CANCER AND METABOLIC TRANSFORMATION 2 
1.1.1 SIX HALLMARKS OF CANCER. AN EMERGING HALLMARK .......................... 2 
1.1.2 METABOLIC REWIRING. WARBURG AND BEYOND ............................................. 3 
1.1.3 METABOLIC REWIRING. ENERGETIC NEEDS OF DIVIDING CELLS .................. 4 
1.2 MAMMALIAN TARGET OF RAPAMYCIN (mTOR) .......................................................... 6 
1.2.1 mTOR OVERVIEW .......................................................................................................... 6 
1.2.2. mTOR STRUCTURE ....................................................................................................... 7 
1.2.3 mTOR COMPLEX COMPOSITION ................................................................................ 8 
1.2.4. mTOR SIGNALING ......................................................................................................... 9 
1.3 PHOSPHOLIPASE D (PLD) AND PHOSPHATIDIC ACID (PA) ................................... 11 
1.3.1 PLD AND PA OVERVIEW ......................................................................................... 11 
1.3.2 MANY SOURCES AND DESTINATIONS OF PA ................................................... 12 
1.4 mTOR REGULATION BY PLD AND PA ......................................................................... 15 
1.4.1 mTOR and PA .............................................................................................................. 15 
1.4.2 mTOR, PLD, PA AND HUMAN CANCERS. METABOLIC SENSING .................. 17 
1.4.3 DIFFERENTIAL REGULATION OF mTOR BY PA ................................................ 18 
1.5 RAS IN CANCERS. RAS-MEDIATED ACTIVATION OF PLD ................................. 20 
1.6 PROJECT RATIONALE ........................................................................................................ 21 
1.7 TARGETING METABOLIC PATHWAYS IN HUMAN CANCERS ................................. 21 
CHAPTER II ................................................................................................................................. 23 
METHODS AND MATERIALS .................................................................................................. 23 
2.1 CELLS, CELL CULTURE CONDITIONS ....................................................................... 24 
ix 
 
2.2 MATERIALS ...................................................................................................................... 24 
2.3 LIPID MIX SUPPLEMENTATION .................................................................................. 24 
2.4 TRANSIENT TRANSFECTIONS ..................................................................................... 25 
2.5 CELL PROLIFERATION .................................................................................................. 25 
2.6 PLD ACTIVITY ................................................................................................................. 25 
2.7 WESTERN BLOT ANALYSIS ......................................................................................... 26 
2.8 FLOW CYTOMETRIC ANANLYSIS ............................................................................... 26 
2.9 IMMUNOPRECIPITATION .............................................................................................. 27 
2.10 LIPID UPTAKE VISULIZATION ................................................................................... 27 
2.11 PA SUPPLEMENTATION .............................................................................................. 28 
CHAPTER III ............................................................................................................................... 29 
Ras-DRIVEN CANCERS DISPLAY INCREASED SENSITIVITY TO LIPID WITHDRAWAL
 ....................................................................................................................................................... 29 
3.1 LIPID DEPRIVATION LEADS TO INCREASED PLD ACTIVITY IN Ras-DRIVEN 
HUMAN CANCER LINES ...................................................................................................... 30 
3.2 Ras-DRIVEN CANCER CELLS ARE UNIQUELY DEPENDENT ON EXOGENOUS 
SUPPLY OF FATTY ACIDS FOR CELL PROLIFERATION AND SURVIVAL ................ 32 
3.3 ONCOGENIC Ras PREVENTS INDUCTION OF STEAROYL-CoA DESATURASE-1 
UPON SERUM AND LIPID WITHDRAWAL ....................................................................... 39 
CHAPTER IV ............................................................................................................................... 42 
LIPID WITHDRAWAL CREATES SYNTHETIC LETHALITY FOR RAPAMYCIN IN Ras-
DRIVEN CANCERS .................................................................................................................... 42 
4.1 WITHDRAWAL OF SERUM LIPIDS CREATES SYNTHETIC LETHALITY FOR 
RAPAMYCIN IN CANCERS HARBORING MUTANT Ras. ............................................... 43 
4.2 SUPRESSION OF MACROPINOCYTOSIS SENSITIZES Ras-DRIVEN CANCER 
CELLS TO RAPAMYCIN ....................................................................................................... 46 
4.3 POSSIBLE MECHANISM OF LIPID UPTAKE IN Ras-DRIVEN CELLS ..................... 49 
CHAPTER V ................................................................................................................................ 51 
LIPID SENSING BY mTOR ........................................................................................................ 51 
5.1 NATURE OF THE FA INFLUENCES mTOR RESPONSE ............................................. 52 
5.2 EIPA TREATMENT LEADS TO DISSOCIATION OF MTORC1 COMPLEX, 
FURTHER ENHANCING EFFECT OF RAPAMYCIN ......................................................... 54 
x 
 
5.3 PA SUPPLEMENTATION RESCUES EIPA-INDUCED DISACTIVATION OF 
mTORC1 ................................................................................................................................... 56 
CHAPTER VI ............................................................................................................................... 58 
DISCUSSION ............................................................................................................................... 58 
6.1 Ras-DRIVEN CELLS ARE HIGHLY DEPENDENT ON EXOGENOUS SUPPLY OF FA
 ................................................................................................................................................... 59 
6.2 ONCOGENIC Ras ALTERS EXPRESSION LEVEL OF SCD1 ...................................... 60 
6.3 LIPID WITHDRAWAL AND RAPAMYCIN CREATES SYNTHETIC LETHAL 
EFFECT ON Ras-DRIVEN CELLS ......................................................................................... 61 
6.4 DIETARY LIPIDS DISPLAY AN ACTIVATORY EFFECT ON mTOR ........................ 62 
6.5 LIPID SENSING BY mTOR .............................................................................................. 64 
6.6 SIGNIFICANCE ................................................................................................................. 64 
6.7 FUTURE DIRECTIONS .................................................................................................... 65 
6.8 HOW IT ALL FITS WITHIN THE CELL ......................................................................... 67 
CHAPTER VII WORKS CITED .................................................................................................. 69 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
List of abbreviations  
4E-BP1: eIF4E-binding protein 1  
ACC: acetyl-CoA carboxylase  
acetyl-CoA: acetyl-coenzyme A  
ACLY: adenosine triphosphate (ATP)-citrate lyase  
CL: cardiolipin  
DG: diacylglycerol 
DGK: diacylglycerol kinase  
DHAP: dihydroxyacetone phosphate 
FA: fatty acid 
FAT domain: FRAP-ATM-TRAAP domain 
FKBP12: FK506-binding protein 12 
G3P: glycerol 3-phosphate 
HEAT domain: Huntingtin, elongation factor 3, alpha-regulatory subunit of protein phosphatase 
2A and TOR1 domain  
LPAAT: lysophosphatidic acid acyltransferase  
mLST8: mammalian lethal with sec-13 protein 8  
mSin1: mammalian stress-activated map kinase-interacting protein 1  
mTOR: mechanistic Target of Rapamycin 
mTORC1: TOR complex 1  
mTORC2: mTOR complex 2  
PA: phosphatidic acid 
PG: phosphatidylglycerol 
PI: phosphatidylinositol 
PI-3K: phosphatidylinositol 3-kinase   
PLC: phospholipase C  
PLD: phospholipase D 
PRAS40: proline-rich Akt substrate 40 kDa  
protor1/2: protein observed with rictor 1 and 2  
raptor: regulatory-associated protein of mammalian target of rapamycin 
Rictor: rapamycin-insensitive companion of mTOR  
S6K1: S6 kinase 1  
SCD: stearoyl-CoA desaturase-1  
 
 
 
 
 
 
 
 
 
 
xii 
 
List of Figures and Tables 
 
Figure 1. The Seven Hallmarks of Cancer and Their Links to Tumor Metabolism……….4 
Figure 2. Structure of mTOR…………………………………………………………………..8 
Figure 3. mTORC1 and mTORC2  components and their known functions……………….9 
Figure 4. mTORC upstream input and downstream output………………………………..10 
Figure 5. Phosphatidic acid metabolism………………………………………………………14 
Figure 6. Conservation of PA-binding domain of mTOR……………………………………16 
Figure 7. Regulation of mTOR by PA species………………………………………………...19 
Figure 8.  Elevated PLD activity in response to serum withdrawal in Ras-driven cancer cell 
lines is dependent on withdrawal of both growth factors and lipids………………………..31 
Figure 9.  Ras-driven cancer cells are uniquely dependent on exogenous fatty acids……..34 
Figure 10.  Ras-driven cancer cells are uniquely dependent on exogenous fatty acids……35 
Figure 11. Re-addition of FA in the absence of growth factors leads to normal cell cycle 
profile in Ras-driven cells………………………………………………………………………36 
Figure 12. Expression of K-Ras V12G sensitized the BJ cells to the lack of lipids in the media 
……………………………………………………………………………………………………38 
Figure 13. Oncogenic Ras leads to ablation of stearoyl-CoA desaturase-1 levels…………..41 
Figure 14. High dose rapamycin, previous findings………………………………………….44 
Figure 15. Protection of rapamacyn-induced apoptosis by serum requires both lipids and 
growth factors…………………………………………………………………………………..45 
Figure 16. Protection of rapamacyn-induced apoptosis by serum requires both lipids and 
growth factors…………………………………………………………………………………..46 
Figure 17. Blockage of micropinocysis mimics lipid deprivation and sensitizes Ras-driven 
tumors to mTOR inhibitors……………………………………………………………………47 
Figure 18. Blockage of micropinocysis mimics lipid deprivation and sensitizes BJ cells 
expressing oncognenic Ras to mTOR inhibitors……………………………..………………48 
xiii 
 
Figure 19. EIPA treatment leads to reduced rate of macropinocytosis and lipid uptake…50 
Figure 20. Nature of FA and cell type influences mTOR response…………………………53 
Figure 21. Inhibition of mTOR with EIPA treatment……………………………………….54 
Figure 22. EIPA treatment leads to mTORC1 and mTORC2 dissociation…………….…..56 
Figure 23. Supplemenation with mono-unsatureated PA but not saturated PA leads rescue 
of EIPA-induced mTOR dissociation…………………………………………………………57 
 
 
Table 1. Lipid mixture composition…………………………………………………………..32 
Table 2. Cell cycle profile in Ras-driven cells………………………………………………..37 
Table 3. Cell cycle profile in BJ cells with or without activated Ras expression…………..39 
Table 4. Cell cycle profile of BJ  and MDA-MB-231 cells showing subgenomic DNA level 
when exposed to mTOR inhibitor, rapamycin, and EIPA…………………………………..48 
 
 
  
1 
    
 
 
 
 
 
 
  
CHAPTER I 
INTRODUCTION 
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1.1. CANCER. HALLMARKS OF CANCER AND METABOLIC 
TRANSFORMATION 
 
1.1.1 SIX HALLMARKS OF CANCER. AN EMERGING HALLMARK  
 
          Cancer, a disorder first written record of which appears in 3000BC [1] and known 
medically as malignant neoplasm, is a broad number of diseases that involves unregulated cell 
growth [2, 3]. In order for a cell to reach cancerous state, six biological capabilities must be 
acquired, described in Weinberg’s review, Hallmarks of Cancer [4]. These include ensuring 
sustained proliferative signaling, or growth factor independence, circumventing actions of 
growth factor suppressors, evasion of cell-to-cell “contact inhibition” and activation of 
extravasation, leading to malignant invasiveness, resisting cell death, enabling replicative 
immortality and inducing angiogenesis. An emerging attribute of cancer phenotype also involves 
a major reprogramming and rewiring of cellular metabolic machinery for sustained cell growth 
and proliferation [5-9]. Not surprisingly, major metabolic sensing machinery, 
mammalian/mechanistic Target of Rapamycin (mTOR), is commonly upregulated in cancers 
[10-12]. Here, I will provide evidence for an additional role of mTOR as a metabolic sensor of 
lipid sufficiency that, when deregulated, contributes to cancer cell survival. 
 
 
 
 
  
3 
1.1.2 METABOLIC REWIRING. WARBURG AND BEYOND  
 
          Cancer cells undergo significant metabolic rewiring and reprogramming that shifts 
metabolic state from catabolic to anabolic state to sustain continuous growth and proliferation 
[13, 14]. Otto Warburg was first to observe that cancer cells display altered metabolic regulation: 
despite having sufficient amount of oxygen for oxidative phosphorylation, cancer cells undergo 
energetically less efficient glycolysis and produce increased amount of lactic acid, the process 
that is famously known as Warburg effect, or aerobic glycolysis [15, 16]. Although the 
observation of the shift to aerobic glycolysis was made more than 80 years ago, the underlying 
mechanism of the shift is not well elucidated and is under close scrutiny [17, 18]. Importantly, it 
is not yet clear whether alterations in cellular metabolism are contributors or mere consequence 
of increased cellular division rate that is observed in normal proliferating tissue [19]. However, 
metabolic shift in cancer cells in not limited to the Warburg phenomenon, as not all cancer cells 
display enhanced uptake of glucose [20]. Nevertheless, it has become well recognized in the past 
decade that a metabolic shift is a necessary occurrence in tumor development and establishment 
to meet increased energetic and anabolic needs of highly proliferative tissue [21, 22]. Moreover, 
it had been established that deregulation of many canonical signaling pathways in tumors lead to 
alterations in metabolic machinery, and mutations that lead to deregulation of cellular 
metabolism are being studied more extensively [5, 7, 9]. A schematic representation of six 
hallmarks of cancer with additional proposed hallmarks and their relation to known metabolic 
reprogramming is shown in Figure 1.   
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1.1.3 METABOLIC REWIRING. ENERGETIC NEEDS OF DIVIDING 
CELLS 
 
           In order for a cell to produce two viable daughter cells, it must replicate all of its cellular 
contents. That would include doubling in nucleic acid content for DNA synthesis, lipid mass, 
proteins and sufficient energy to proceed with mitosis. Thus, cell division imposes large 
  
5 
requirement for exogenously or endogenously derived macromoleclues: ATP, nucleic and amino 
acids and lipids. In addition, the cell must ensure that it could properly sense and determine 
sufficiency of macromolecule precursors to proceed with cell division and produce two viable 
cells.  
           During cell cycle progression, cells in G1 cell cycle commit to dividing via two distinct 
and independent restriction points [23, 24]. Firstly, the cell receives instruction to divide in form 
of growth factors. As mentioned earlier, growth factor dependence in cancer cells is often 
circumvented via various means [4]. Secondly, the cell must ensure that there are sufficient 
resources to proceed with cell division. Increased biosynthesis of macromolecules through 
alternative means is under close research, and much has been learned on how nucleic acids and 
amino acid levels are maintained in cancer cells [25-28]. It is now evident that in addition to 
glucose, cancer cells utilize glutamine as a nitrogen source for nucleotides and as a carbon source 
[29].  Cancer cells also need essential amino acids that mammalian cells cannot synthesize.  
However, an underappreciated aspect of nutrient uptake is the utilization of exogenously 
supplied fatty acids [30].  Cells grown in culture are provided with media that is supplemented 
with glucose, essential amino acids, and glutamine as nutrients for cell growth.  However, 
mammalian cell do not synthesize all of the unsaturated lipids needed for membrane biosynthesis 
– there are “essential fatty acids” that must also be present in the medium  [30]. Conventional 
growth media used for culturing mammalian cells do not contain lipids – they are provided in the 
serum that typically supplement culture media. 
            Thirdly, a nutrient sufficiency sensing mechanism to proceed with mitosis is needed. 
mTOR, which will be described in more detail in a later sector, is a major sensor of amino acid, 
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glucose, energy and stress factors [31, 32]. Although much is known how mTOR serves as a 
responder to nutrients, it is not clear how cells sense presence of sufficient lipid precursors. In 
this work, I will propose that mTOR is indeed a suitable candidate as a sensor of lipid sufficiency 
and show that improper lipid sufficiency sensing represents an Achilles’ heel in a population of 
Ras-driven cancers.  
 
1.2 MAMMALIAN TARGET OF RAPAMYCIN (mTOR)  
 
1.2.1 mTOR OVERVIEW 
 
          Mammalian (or mechanistic) Target of Rapamycin functions as an integrator of nutritional, 
energy and stress status, and its output dictates most major cellular functions that regulate cell 
growth and proliferation. mTOR is an atypical serine/threonine protein kinase that belongs to 
phosphatidylinositol 3-kinase (PI-3K)  related protein kinase family that is conserved from yeast 
to mammals [33]. It received its name from a small molecule rapamycin, which is a macrocyclic 
lactone produced by Streptomyces Hygroscopicus bacteria. Rapamycin has received broad 
attention in clinic because of its antiproliferative and immunosuppressant effects. Rapamycin 
forms a complex with the peptydil-prolyl cis-trans isomerase FKBP12 (FK506-binding protein) 
and the FKBP12-rapamycin complex binds to mTOR and works as an allosteric inhibitor of the 
mTOR kinase [34-36]. mTOR forms a catalytic core of at least two functionally and structurally 
distinct complexes- TOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). These 
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complexes contain shared and unique partners, display differential sensitivity to rapamycin and 
have different upstream inputs and downstream outputs [37, 38].  
          The nomenclature of mTOR has been a subject of a recent debate and, more importantly, 
confusion [39]. TOR has been originally discovered in yeast by Michael Hall’s group [40, 41]. 
As mammalian Target of Rapamycin (mTOR), it has been known for almost two decades since 
the discovery that yeast TOR ortholog exists in mammals [42-45]. However, recently, an 
alternative name, Mechanistic Target of Rapamycin (MTOR), was introduced by database 
curators. The interchangeability of the mTOR/MTOR, mammalian/mechanistic, is not widely 
accepted, and is brining unnecessary confusion to the field. For the simplicity reasons, and since 
it is more appropriate from biological point perspective, here I will use the name of mTOR as 
mammalian Target of Rapamycin.  
1.2.2. mTOR STRUCTURE 
 
           mTOR is a 290 kDa multi domain protein that belongs to PI-3K related kinases. Members 
of this kinase family are characterized by presence of N-terminal HEAT (Huntingtin, elongation 
factor 3, alpha-regulatory subunit of protein phosphatase 2A and TOR1) domain and a kinase 
domain in the C-terminal half that is flanked by the FAT (FRAP-ATM-TRAAP) domain and 
FATC domain. HEAT and FAT domains are involved in protein-protein interactions, while 
FATC domain responds to redox potential [36, 46, 47].  mTOR also possesses self-descriptive 
FKBP12/rapamycin binding (FRB) domain lying between FAT and kinase domains. Schematic 
of the structure is shown in the Figure 2.   
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1.2.3 mTOR COMPLEX COMPOSITION 
 
          mTOR complexes contain shared and unique partners. Each complex contains catalytic 
mTOR subunit, mammalian lethal with sec-13 protein 8 (mLST8), critical for mTOR assembly 
and signaling, DEP domain containing mTOR-interacting protein (DEPTOR), a negative 
regulator of mTOR, and the Tti1/Tel2 complex, which regulates stability and assembly of 
mTOR. mTORC1 contains two unique partners: regulatory-associated protein of mammalian 
target of rapamycin (raptor), a  scaffolding protein that regulates substrate binding, and proline-
rich Akt substrate 40 kDa (PRAS40), a negative regulator of mTORC1. mTORC2 contains the 
following three unique partners: rapamycin-insensitive companion of mTOR (rictor), a 
scaffolding protein that regulates substrate binding, mammalian stress-activated map kinase-
interacting protein 1 (mSin1), and protein observed with rictor 1 and 2 (protor1/2), both of which 
are involved in binding and activation of mTORC2 downstream target SGK1 [37, 38]. In 
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addition, both complexes contain a lipid metabolite, phosphatidic acid (PA), that has been shown 
to be required for the stability and function of the complexes and binds to mTOR in a manner 
that is competitive with rapamycin [48-52]. Figure 3 shows the list of components with their 
known functions.  
 
1.2.4. mTOR SIGNALING  
 
          In essence, mTOR could be viewed as an integrator of diverse cellular cues, and the output 
dictates major steps for cell growth and proliferation. The substrate composition of the mTOR 
complexes dictates the substrate specificity. Little is known on upstream regulation of mTORC2, 
but it is generally agreed that growth factors control mTORC2. mTORC1, regulation of which is 
better understood, integrates growth factor, amino acid, energy and stress. In addition, both 
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mTOR complexes have been shown to be regulated by lipid metabolite, PA. Although it has 
been shown that PA is necessary for mTOR complex formation and stability, the underlying 
involvement of PA in the function of mTOR is not widely accepted. 
           mTORC1 exerts much of it function via two substrates, S6 kinase 1 (S6K1) and eIF4E-
binding protein 1 (4E-BP1), both of which associate with a particular population of mRNAs and 
regulate mRNA translation initiation and progression [53]. mTOR-dependent regulation of 
translation leads to cell growth and proliferation, inhibition of autophagy, macromolecule 
synthesis, including nucleic acids and lipids [27, 54, 55]. Thus, mTOR regulates metabolic 
programs to promote cell growth. Downstream targets of mTORC2, Akt, SGK1 and PKCα are 
essential for promoting cell survival and proliferation as well as regulation of actin cytoskeleton. 
Schematic of mTOR complexes upstream inputs and downstream outputs is shown in Figure 4. 
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We have additionally proposed and additional function of mTOR as a sensor of lipid sufficiency 
[56] that is exerted through PA. 
1.3  PHOSPHOLIPASE D (PLD) AND PHOSPHATIDIC ACID (PA) 
 
1.3.1 PLD AND PA OVERVIEW 
 
          Phospholipase D is an evolutionarily conserved from bacteria to mammals lipase that 
catalyses the hydrolysis of the membrane phospholipid phosphatidylcholine to generate choline 
and the signaling lipid PA. There are two isoforms of PLD (PLD1 and PLD2) that exist in 
mammals that share about 50% of sequence homology. The two mammalian isoforms are 
regulated differently, with PLD2 being active at basal level while PLD1 being responsive to 
growth factors and nutritional stimuli [57-61].  
          PLD has been implicated in a number of cellular activities, including membrane 
trafficking, cytoskeletal reorganization and cell migration, exocytosis and receptor endocytosis 
[62-64]. These functions are vital for the cell survival but are also common contributors to 
tumorigenesis. Not surprisingly, PLD, whose activity is elevated in a large number of human 
cancers, has been implicated in the survival signals that suppress apoptosis when the cells are 
subjected to stress of serum withdrawal [52, 65, 66].  
          PA itself can function as a second messenger to activate various kinases including mTOR. 
In addition, PA is an essential substrate for enzymes involved in the synthesis of 
glycerophospholipids and triacylglycerols, thus, it stands in the center of lipid synthesis, both for 
membrane phospholipids and triglyceride synthesis [56, 67].  The features of PA as a signaling 
  
12 
molecule and as a central metabolite in lipid synthesis place PA in unique position as a sensing 
molecule that would be discussed in later section.  
 
1.3.2 MANY SOURCES AND DESTINATIONS OF PA 
 
          PA is a unique lipid that serves as both signaling molecule and an essential precursor for 
membrane phospholipid and triglyceride synthesis. Schematic representation of sources and 
destinations of PA in lipid metabolism are shown in the Figure 5. Generation of PA for lipid 
synthesis occurs via three distinct mechanisms. The first mechanism involves hydrolysis of 
phosphatidylcholine by PLD to produce PA and free choline. However, it is unlikely that PLD 
produced PA goes into generation of the membrane phospholipid considering that the original 
source is the membrane phospholipid. The second mechanism involves both newly synthesized 
and dietary fatty acids. PA is produced by enzymatic reaction of acylation of glycerol 3-
phosphate (G3P) and two fatty acids (FAs) by two distinct acyltransferases, the last step of which 
is catalyzed by lysophosphatidic acid acyltransferase (LPAAT). Fatty acids for this process could 
be derived from either diet or from newly synthesized FA’s through action of fatty acid synthase 
(FAS). Importantly, this mode of PA generation involved a glycolytic shunt, as G3P is converted 
from dihydroxyacetone phosphate (DHAP), glycolytic pathway intermediate. The third pathway 
involves phosphorylation of diacylglycerol (DG) by DG kinase. DG comes from either stored 
triglycerides that are released by actions of lipase, or in response to growth factor induced 
stimulation of phospholipase C (PLC) from phosphatidylinositol.   
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            Destinations of PA for lipid synthesis are multiple. PA could be converted back to DG 
via action of PA-phosphatase. DG could be acetylated to generate triglycerides for fat storage. 
PA could also be condensated with cytidine triphosphate (CTP) via action of CDP-diacylglycerol 
synthase and utilized immediately for the synthesis of phosphatidylglycerol (PG), and cardiolipin 
(CL), and of phosphatidylinositol (PI) [56, 67] for membrane biosynthesis.  
         Thus, PA stands at the center of the lipid synthesis. Major metabolic enzymes that catalyze 
conversion of PA, LPAAT, PLD and DGK, also regulate the passage of PA into storage mode 
(triglyceride synthesis) or synthetic mode (membrane phospholipids). Given the central location 
of PA in lipid metabolism, and its input into mTOR, we have speculated that PA requirement of 
mTOR has evolved as a responsiveness of mTOR to the presence of sufficient lipid precursors.  
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1.4 mTOR REGULATION BY PLD AND PA 
 
1.4.1 mTOR and PA 
 
          PA has been shown to be a critical activator of mTOR signaling. It has been shown that 
PA binds to mTOR in a manner that is competitive with rapamycin [52], and PA-mTOR 
interaction is required for the stability of the complexes [50, 51]. In vitro, PA physically 
associates with the FRB domain of mTOR, and this lipid-protein interaction is highly specific for 
PA [48]. In addition, the PA-FRB domain association is disrupted by the FKBP12-rapamycin, 
indicating competitive manner of the binding between PA and FKBP12-ramapycin to mTOR. 
Solution of the PA-FRB complex structure using NMR spectroscopy also confirmed mutually 
exclusive mode of FRB binding to PA and/or  FKBP12-rapamycin [68]. It also showed a critical 
role of amino acid residue at the FRB domain, Arg2109, for PA binding. Of a note, the site of 
PA-FRB domain interaction is highly conserved from yeast to humans, with slight variation of 
positively charged amino acids, Arg or Lys, at the site [56]. Schematic representation of PA-
binding domain of mTOR is shown in Figure 6. It is somewhat evident that the strict 
conservation of Arg2109 at the FRB domain of mTOR was maintained not for the purpose of 
creating sensitivity for rapamycin. 
          There are multiple sources of PA in the cell that contribute to activation of mTOR. PLD is 
an obvious source, and overexpression of either PLD1 or PLD2 activates mTORC1 in various 
cells[50]. However, recent reports have showed that whole organism knockout of both PLD1 and 
PLD2 is viable [69, 70], while mTOR knockouts are embryonic lethal[71, 72], indicating that PA 
must be used from different sources. Two additional PA-producing enzymes, lysophosphatidic 
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acid acyltransferase (LPAAT) and diacylglycerol kinase (DGK), have also been shown to 
regulate mTOR signaling through PA [73, 74].  
           Thus, a lot of evidence indicates PA involvement in mTOR regulation that go beyond 
mTOR modulation by PLD. However, the relevant cause for the downstream PA-mTOR 
signaling remains elusive. It is clear that PA stands at the center of lipid metabolism. In addition, 
it serves as a signaling molecule to activate major metabolic sensing machinery in the cell, 
mTOR. Taken these information together, it had been proposed that PA feeds into mTOR as an 
indicator of lipid sufficiency in the cell [56].  
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1.4.2 mTOR, PLD, PA AND HUMAN CANCERS. METABOLIC SENSING 
 
         PLD could be in essence viewed as an oncogene. Its activity had been shown to be 
upregulated in numerous cancers, contributing to survival signals and transformation [66, 75]. 
PLD activity is also strongly increased in Ras-driven cancer cells, and PLD1 activity has been 
shown to be required for Ras-induced transformation [76, 77].  
         mTOR has key roles in regulation of many anabolic and catabolic pathways that are 
involved in cell proliferation and survival, and it is not a surprise that upstream signals that 
regulate mTOR are the most commonly dysregulated in cancer [10, 11]. In addition, there are 
reports of gain-of-function mutations in mTOR protein itself, though these are less common [78]. 
mTOR significantly contributes to metabolic reprogramming in cells. Increase in ribosome 
biogenesis linked to mTOR activation probably promotes cell proliferation by providing the 
machinery required to sustain high levels of cell growth. Dysregulation of cap-dependent 
translation that is regulated by mTORC1 promotes cell-cycle progression and cell proliferation 
[79]. Increased de novo lipid biosynthesis is an additional absolute requirement for proliferating 
cancer cells to support synthesis of new membranes [80]. mTORC1 has been shown to be 
required for the activation of the prolipogenic factor SREBP1, a master regulator of lipo- and 
sterolgenic gene transcription [81]. Thus, mTOR not only responds to nutrients and energy, but 
also contributes to metabolic reprogramming to promote cell survival and proliferation.  
         PLD has been known to respond to mitogenic stimuli, and subsequently feed on mTOR for 
quite some time [48, 82]. The regulatory role of PLD on mTOR is also extended as a sensor of 
  
18 
amino acid sufficiency [60, 61, 83]. However, it is becoming more evident that regulation of 
mTOR by PA is accomplished not only from the hydrolysis of phosphatidylcholine by PA, but 
also through PA generated from de novo synthesis pathways (reviewed in [56]). Thus, regulation 
of mTOR by PA could be extended beyond its regulation by PLD.  
          Importantly, both LPAAT and DG kinase have been shown to stimulate mTOR [73, 74]. 
Moreover, suppression of LPAAT, which is responsible for de novo synthesized and dietary 
lipids, suppressed mTOR activity and disrupted survival and proliferative signals in several 
cancer cell lines [84]. Thus, there is a link between mTOR activation and de novo lipid synthesis 
through PA. PA hence is proposed to serve as a metabolic sensor to mTOR to corroborate 
sufficiency of lipid precursors in proliferating cell [56].  
1.4.3 DIFFERENTIAL REGULATION OF mTOR BY PA 
 
          Most mammalian cells acquire lipids from the diet, however, actively dividing cells have 
absolutely depend on de novo lipid synthesis [85, 86]. De novo lipid synthesis is largely 
catalyzed by fatty acid synthase (FASN), and levels of FASN are expressed in high level in 
many cancers and linked to poor outcome [87-89]. The acetyl groups for fatty acid synthesis 
come from citrate, using either glucose or glutamine as an anaplerotic carbon source for TCA 
cycle intermediates [90, 91]. Citrate is converted into acetyl-coenzyme A (acetyl-CoA) by 
adenosine triphosphate (ATP)-citrate lyase (ACLY), and acetyl-Co A is converted to malonyl-
CoA by acetyl-CoA carboxylase (ACC). Subsequent steps of fatty acid synthesis are 
accomplished by FASN, and the final generated product is palmitic  acid, a basic 16-carbon 
saturated fatty acid [92]. Palmitate could be elongated to stearate and then desaturated by 
stearoyl-CoA desaturase-1 (SCD1) to form monounsaturated oleic acid. 
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           The generated FA could be incorporated into membrane biosynthesis with the help of 
acyltransferases. However, the lipid species that come from de novo synthesis are either 
completely saturated, or have one desaturated group. Hence, mammalian cells require 
exogenously supplied unsaturated fatty acids, essential fatty acids, such as linoleic and linolenic, 
which contain 2 and 3 double bonds respectively [93, 94]. 
          Recent reports had shown that there is differential activation of mTOR by completely 
saturated vs. partially unsaturated PA species. PA species with two saturated palmitates had been 
shown to inhibit mTORC2 [95], while 1-palmitoyl, 2-oleoyl-PA is stimulatory for both 
mTORC1 and mTORC2 [51, 96]. Thus, some degree of desaturation on PA is needed for 
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activation of mTOR.  Alternatively, it is possible that only PA species with some degree of 
desaturation lead to stabilization of the complexes, while completely saturated PA species 
binding leads to dissociation of mTOR complexes. Schematic of mechanistic sensing of PA 
species by mTOR is shown in the Figure 7.  PA exerts its regulatory function on mTOR by 
activating mTOR with PA some level of desaturation, and thus shifting metabolic machinery to 
produce membrane phospholipids. Alternatively, PA species with two saturated FAs inhibit 
mTOR, and the majority of saturated PA is shunted into storage mode.  
1.5  RAS IN CANCERS. RAS-MEDIATED ACTIVATION OF PLD 
 
         Ras GTPases (H, K, N-Ras) are the key proteins in eukaryotic signal transduction directed 
toward cellular proliferation and differentiation, and it regulates a myriad of pathways in the cell. 
The biological activity of Ras is regulated by GDP/GTP loading cycle. Guanine nucleotide 
exchange factors (Ras-GRF, Sos) induce dissociation of GDP from Ras-GDP to form an active, 
GTP-bound form of Ras. GTP-ase activating proteins (NF1, p120GAP) accelerate the intrinsic 
GTP hydrolytic activity of Ras to promote the formation of an inactive GDP-Ras [97-99]. Not 
surprisingly, one of the most common gain of function mutations found in human cancers are 
activating mutations to genes encoding Ras family GTPases [100], with 30% of all cancers and 
90% of all pancreatic cancers carrying Ras mutation that are thought to be driver mutations 
[101].  
         Many cancer cell lines with elevated PLD activity have activating mutations in Ras [77]. In 
addition, activated Ras had been shown to stimulate increases in PLD activity. Moreover, PLD1 
isoform is constitutively associated with RalA[102], a downstream target of Ras [103]. Thus, a 
critical target of Ras signaling in cancer pro-survival could be PLD.  
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1.6 PROJECT RATIONALE  
 
          Cancer cells have been shown to be efficient in ignoring many signals to which normal 
cells respond. Metabolic signals are no exception. It is proposed that cancer cells rewire and trick 
metabolic sensing into “thinking” that there is sufficient amount of lipid precursors. The PA 
species, most commonly associated with mTOR regulation, is generated by the hydrolysis of 
phosphatidylcholine by PLD. However, reports have revealed that dual PLD1 and PLD2 
knockouts are viable [69, 70], while mTOR knockouts are embryonic lethal [72]. Thus, if PA is 
essential for mTOR activity, then other sources of PA must be utilized. The two candidate 
compensatory pathways for PA production into mTOR are LPAAT and DGK pathways. Of 
interest, LPAAT-derived PA is derived from exogenously provided fatty acids.  
          mTOR has long been known to respond to amino acids, glucose and energy. However, 
lipids are another essential nutrient, and sensing mechanism on sufficiency of lipid precursors is 
not yet known.  Based on the central position of PA in lipid biosynthesis, and its involvement in 
mTOR regulation, we set forth to investigate the requirement of PA in regulating mTOR as a 
more evolutionary primitive mechanism of sensing lipid precursors.  
1.7 TARGETING METABOLIC PATHWAYS IN HUMAN CANCERS  
 
          Altered metabolic programs in cancer cells are crucial for supporting increased 
proliferation and growth. However, metabolic reprogramming also makes cancer cells more 
dependable on their new rewired metabolic network. Thus, one of the emerging fields of cancer 
therapeutics is the possibility of targeting the special metabolic needs of cancer cells [5, 
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104].There has been considerable enthusiasm about the possibility of interfering with both 
glucose [105] and glutamine [29] utilization as therapeutic options for human cancers.  However, 
strategies that target enhanced dependence on glucose in cancer cells have been so far not very 
successful [106, 107]. Thus, there is a clear need to explore other metabolic processes that could 
be therapeutically targeted.      
         Interfering with fatty acid metabolism has received some attention. Most of the studies 
target de novo synthesis of FA in cancer cells [92, 108], and FASN has emerged as an attractive 
target for cancer therapy, and several compounds are known to inhibit FASN. These include 
cerulenin, C75, orlistat, C93 and naturally occurring polyphenols. However, overexpression of 
FASN in many tumors has created FASN inhibition ineffective [109]. Although lipids could be 
synthesized in the proliferating cells, a portion of lipids are acquired from bloodstream. There 
has been very little reported on the utilization of exogenously supplied lipids and the therapeutic 
options of inhibition of lipid uptake.  
         The most likely way to produce cytotoxic effect is by creating synthetic lethality, or 
blockage of several pathways that cells depend on. mTOR integrates signals that respond to 
nutrients and promotes cell cycle progression and cell survival [110].  We have previously 
reported that suppression of mTOR in the absence of serum results in apoptosis in cancer cells 
harboring mutant Ras genes in the absence of serum [111-113].  Here, we identify an enhanced 
need for exogenously supplied serum lipids in Ras-driven human cancer cell lines that creates a 
synthetic lethality[114] for suppressing mTOR.  This finding could be therapeutically targeted in 
what may be as many as 30% of all human cancers. 
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2.1 CELLS, CELL CULTURE CONDITIONS 
 
           The MDA-MB-231, Calu-1, BJ, MCF7, BxPC3, T24, HT29, Panc-1, HCT116 cell lines 
used in this study were obtained from American Type Culture Collection. Cell lines were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma) supplemented with 10% 
FBS (Sigma).  BxPC3 cell line was maintained in Roswell Park Memorial Institute (RPMI) 
(Sigma) medium supplemented with 10% FBS. Delipidated FBS was obtained from Gemini Bio 
Products (900-123).  
2.2 MATERIALS 
 
            Reagents were obtained from the following sources. Antibodies against Cleaved PARP, 
actin, Akt, P-Akt (Ser473), P-Akt (Thr308), S6 kinase, P-S6 kinase (Thr389), 4EBP1, P-4EBP1 
(Thr37-46), FASN, SCD1, ACL were obtained from Cell Signaling; antibodies against KRas 
were obtained from Abcam. MTT reagent was obtained from Sigma.  Rapamycin was obtained 
from LC Labs, and EIPA was obtained from Sigma.  
2.3 LIPID MIX SUPPLEMENTATION 
 
           Fatty acid mix was obtained from Invitrogen (11905) and was supplied to cells as 1:200 
dilution complexed with 10% BSA (Sigma) in 2 to 1 ratio for the final concentration of lipids in 
the media of 0.375 mg/L.  The exact composition of the fatty acid mixture is provided in Table 
S1.  Palmitic acid (Sigma) was diluted in Pluronic F-68 (Gibco, 24040) and supplied to the cells 
in the complex with BSA to the final concentration of lipids of 0.2 mg/L.  The reduced level of 
lipid used was due to cytotoxicity of higher concentrations palmitic acid.  
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2.4 TRANSIENT TRANSFECTIONS 
 
          Plasmids for transient transfections were obtained from the following sources: 
constitutively active KRas (Missouri S&T cDNA Resource Center, RASK2000C0), pcDNA3.1 
verctor (Invitrogen).  For transient transfections, cells were plated at 3x103 cells/6-well plate (cell 
proliferation assay) or at 30% confluence/60-mm plate (flow cytometry assay), overnight, and 
transfected using Polyfect (Qiagen) according to manufacturer’s instructions. 18 hours post-
transfection, cells were shifted to conditions as described in the text and figure legends.  
2.5 CELL PROLIFERATION 
 
           Cells 6-well plates at 3,000 cells per well in 2 ml of full serum media overnight and 
shifted to various lipid conditions the next day. Media was not changed throughout the course of 
the experiment. After 5 days, cell number was determined by counting viable (adherent) and 
non-viable (floating) cells using hemocytometer.  The MTT cell viability/growth assay, which 
measures NAD(P)H dependent anabolic activity was performed according to the vendors 
(Sigma) instructions. 
2.6 PLD ACTIVITY 
 
          PLD was determined by accumulation of the transphosphatidylation product [3H]-
phosphatidylbutanol as described previously [51].  Lipid membranes were labeled with [3H]-
myristic acid (60 Ci/mmol; 1.5 µCi/ml; Perkin-Elmer) for 4 hours. 1-BtOH was added for 20 min 
before lipids where collected. Lipids were extracted and separated by thin layer chromatography 
along with phosphatidylbutanol standard (Enzo Life Sciences, BML-ST401-0050).  The 
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phosphatidylbutanol fraction was identified through co-migration with standards and the levels 
of the PLD product [3H]-phosphatidylbutanol was determined by scintillation counting. 
2.7 WESTERN BLOT ANALYSIS 
 
            Proteins were extracted from cultured cells using M-PER (Thermo Scientific, 78501). 
Equal amounts of proteins were subjected to SDS-PAGE on poly-acrylamide separating gel, and 
the electrophorezed proteins were transferred onto nitrocellulose membrane. The nitrocellulose 
membrane containing proteins was blocked in 5% non-fat dry milk solutions in PBST. 
Membranes were incubated in primary antibodies overnight, and secondary antibodies for an 
hour. Detection of proteins was performed using ECL system (Thermo Scientific). 
2.8 FLOW CYTOMETRIC ANANLYSIS 
 
          Cultured cell were washed and collected via trypsinazation. Recovered cells were 
resuspended in the solution containing 7 ml of 2% bovine serum albumin in phosphate buffered 
saline, 5mM EDTA, 0.1% NaN3 and fixed by drop wise addition of 3ml of 100% ethanol. Fixed 
cells were collected and resuspended in 500 µl of sorting buffer containing 2% bovine serum 
albumin in phosphate buffered saline, 0.1% Triton-X 100, 5mM EDTA, 40µg/ml propidium 
iodide, 100µg/ml RNAse A, and incubated at 37C for 30 min.  The cells were filtered through 
70-µm mesh to remove cell aggregates. The DNA content was analyzed by flow cytometry 
(FACSCalibur; Becton Dickinson), and percentages of cells within each phase of the cell cycle 
were determined using WinCycle software (Phoenix Flow Systems). 
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2.9 IMMUNOPRECIPITATION  
 
          Cells were grown in 6-well plates. Before lysing, cells were washed with cold PBS and 
lysed on ice for 5 min with 100µl of ice-cold 0.3% CHAPS IP buffer (40 mM HEPES [pH 7.5], 
120 mM NaCl, 1mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 50 mM NaF, 0.5 
mM orthovandate, protease and phosphates inhibitors). Approximately 200 µg of protein was 
incubated with appropriate antibodies for 4 hours, and immunoprecipitated were recovered using 
protein G sepharose. The immunoprecipitates were later subjected to Western blot analysis along 
with total cell lysate. 
 
2.10 LIPID UPTAKE VISULIZATION  
 
          Cells were grown on 25-mm sterile, acid-etched plates containing glass coverslip until 
50% confluency was reached. For the lipid uptake, cells were washed with Hank’s solution, and 
incubated in serum-free media with fluorescently tagged lipid vesicles (20 µM BODYPY 
500/510C12 (Invitrogen), 20 µM lipid mix in delipidated BSA (1:1 molar ratio) for 30 min at 10 
ºC, and rinsed with Hank’s solution twice to remove unbound lipid vesicles. Warm serum-free 
media was added for 5 min immediately before visualization using Nikon E800 spinning disc 
confocal microscope using X60 objective. 
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2.11 PA SUPPLEMENTATION 
 
Right before supplementation, the appropriate amount of PA was dried under N2, and 
resuspended  by votexing and sonicating in D-PBS for 5 minutes. The resulting PA suspension 
was immediately added to cell culture to the final concentration of 100µM. Due to short half-life 
of PA, this process was repeated every one hour throughout treatment. 
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CHAPTER III 
Ras-DRIVEN CANCERS DISPLAY INCREASED SENSITIVITY TO LIPID 
WITHDRAWAL 
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3.1 LIPID DEPRIVATION LEADS TO INCREASED PLD ACTIVITY IN 
Ras-DRIVEN HUMAN CANCER LINES 
 
          We previously reported that serum withdrawal led to an increase in phospholipase D 
(PLD) activity that was largely restricted to cancer cells harboring Ras mutations [111].  PLD 
generates phosphatidic acid (PA) from phosphatidylcholine, which is required for the stability 
and activity of mTOR complexes [48, 51].  mTORC1 is a sensor of nutrients that regulates both 
cell cycle progression and survival [115].  It has been suggested that activation of the mTOR 
signaling node is the most commonly dysregulated signal in human cancers [10, 116].  Since PA 
is at the center of membrane phospholipid biosynthesis, we recently proposed that PA impacts 
upon mTOR as an indicator of sufficient precursors for membrane synthesis in dividing cells and 
that cancer cells have co-opted PLD to sustain cell proliferation and survival of cancer cells by 
providing the PA needed to keep mTOR active [117].  Thus, we speculated that the increased 
PLD activity observed in K-Ras-driven cancer cells could be a response to insufficient lipids in 
serum.  To test this hypothesis, we examined the impact of serum lipids on the PLD activity 
stimulated by the withdrawal of lipids from MDA-MB-231 breast, Calu-1 lung, and T24 bladder 
cancer cells – all of which harbor mutant Ras genes and were previously shown to elevate their 
PLD activity is response to serum withdrawal [111].  Replacing 10% fetal bovine serum (FBS) 
with 10% delipidated FBS resulted in an increase in PLD activity in all three cell lines that was 
almost as robust as that observed with complete withdrawal of FBS (Figure 8).  If a mixture of 
fatty acids (FAs) consisting of saturated, mono-unstaurated, and poly-unsaturated FAs (Table 1), 
was substituted for the FBS, elevated PLD activity was still observed – indicating that the lack of 
serum growth factors also contributed to the elevated PLD activity.  Importantly, if the 
delipidated FBS was combined with the FA mixture, PLD activity was restored to the basal level 
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observed in the presence of serum.  These data demonstrate that the elevated PLD activity 
observed in response to serum withdrawal in Ras-driven human cancer cells is due in part to the 
absence of serum lipids.  
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3.2 Ras-DRIVEN CANCER CELLS ARE UNIQUELY DEPENDENT ON 
EXOGENOUS SUPPLY OF FATTY ACIDS FOR CELL PROLIFERATION 
AND SURVIVAL  
 
           Elevated PLD activity promotes survival is response to stress in Ras-driven cancer cells 
[111].  To test whether the increased PLD activity in Ras-driven cell lines yields in proliferative 
advantage, we investigated the dependence on serum lipids of a subset of human cancer cell lines 
for cell proliferation and viability.  MDA-MB-231 breast and Calu-1 lung cancer cells both 
harbor K-Ras mutations; whereas MCF-7 breast cancer cells and the diploid human fibroblast BJ 
hTERT cells do not.  Cells were plated and after 24 hr were shifted to the indicated conditions.  
After 5 days, viable and non-viable cells were counted.  For all three cancer cell lines, there were 
very few viable cells after 5 days when put in medium lacking FBS (Figure 9).  In contrast, 
almost all of the BJ cells were still viable.  If the cells were put in medium containing 10% 
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delipidated FBS, virtually all of the Ras-driven MDA-MB-231 and Calu-1 cancer cells, were 
non-viable, whereas the MCF7 and BJ cells were mostly viable – indicating a significant 
difference in the way that Ras-driven cancer cells respond to the lack of serum lipids.  Most 
strikingly, when the FA mixture was provided to the K-Ras-driven MDA-MB-231 and Calu-1 
cells, there was a dramatic increase in cell viability relative to the viability observed with 
delipidated FBS – indicating a greater dependence on lipids than growth factors for both 
proliferation and survival (Figure 9).  Both the MCF7 and BJ cells had lower cell numbers with 
the FA mixture than with the delipidated FBS – indicating a greater dependence on growth 
factors than lipids for proliferation.  The combination of delipidated FBS and the FA mixture 
restored full proliferation and survival to all cell lines.  Of interest, a lipid mixture that contained 
only palmitic acid (PA), the sixteen carbon saturated fatty acid produced by de novo fatty acid 
synthesis, did not enhance either survival or proliferation – indicating that the longer chain 
unsaturated fatty acids present in the FA mixture were critical.  Similarly, bovine serum albumin 
(BSA), which was included as a carrier for the FA’s, did not improve survival of the MDA-MB-
231 or Calu-1 cells in 10% delipidated FBS.  The pattern of a greater dependence of lipids than 
growth factors for Ras-driven cancer cells was also observed with a larger panel of human cancer 
cell lines (Figure 10). 
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 We next compared the effect of serum deprivation and serum deprivation + FAs on cell 
cycle progression using flow cytometry.  All four cell lines (BJ, MCF7, MDA-MB-231, and 
Calu-1) had increased G1 DNA content when cells were shifted from 10% FBS to 0% FBS 
(Figure 11, left panel).  However, if the cells were shifted to 0% FBS in the presence of the FA 
mixture, the BJ and MCF7 cells still arrested in G1, whereas the K-Ras-driven MDA-MB-231 
and Calu-1 cells did not significantly accumulate in G1.  Similarly, there was a reduction of cells 
in S-phase for all cell lines when placed in 0% FBS (Figure 11, right panel). However if the FA 
mixture was provided, there was still a reduction in S-phase cells in the BJ and MCF7 cells, but 
not so in the MDA-MB-231 and Calu-1 cells. Raw cell cycle profile numbers of cell types 
screened are depicted in Table 2. These data demonstrate that the MDA-MB-231 and Calu-1 
cells harboring K-Ras mutations could sufficiently resume normal cell cycle with addition of FA 
alone.  In contrast, the MCF7 and BJ cells accumulated in G1 in the absence of growth factors  
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and the addition of lipids did not make a difference.  Thus, K-Ras-driven cancer cells have a 
greater dependence on exogenously supplied lipids and a lesser dependence on serum growth 
factors than the BJ and MCF7 cells. 
          To further demonstrate that mutant Ras promotes a dependence on lipids, we transfected 
the BJ cells with a plasmid expressing oncogenic K-Ras (K-RasV12G).  Parental BJ cells 
transiently transfected with K-Ras-expressing and empty vector plasmids were shifted to 
medium containing 0% FBS and 0% FBS containing the FA mixture and the relative cell 
numbers were determined three days later.  The cells transfected with the K-RasV12G plasmids 
had significantly fewer cells in the absence of FBS than the control BJ cells transfected with 
vector alone (Figure 12).  However, if FAs were included with the medium lacking FBS, then the 
RasV12G-transfected BJ cells grew as well as the parental BJ cells – indicating that expression of 
K-RasV12G sensitized the BJ cells to the lack of lipids in the media.  
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3.3 ONCOGENIC Ras PREVENTS INDUCTION OF STEAROYL-CoA 
DESATURASE-1 UPON SERUM AND LIPID WITHDRAWAL  
 
The above results clearly indicate a differential response to lipid deprivation in cells 
expressing mutant Ras.  Key enzymes in the generation of fatty acids needed for membrane 
biosynthesis include fatty acid synthase (FASN), ATP citrate lyase (ACL), and stearoyl-CoA 
desaturase-1 (SCD1) [108].  We examined the effect of serum and lipid withdrawal on the levels 
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of these three enzymes in the BJ, MCF7, and MDA-MB-231 cells (Figure 13a).  While no 
significant changes in expression levels of FASN and ACL were detected in response to serum 
or lipid withdrawal, there was a dramatic increase in the level of SCD1 in the BJ and MCF7 
cells. In contrast, the MDA-MB-231 cells did not elevate SCD1 expression in response to serum 
and lipid deprivation (Figure 13a).  Similarly, if the K-RasV12G expressing plasmid was 
transfected into BJ cells, it suppressed the elevated expression of SCD1 observed in response to 
serum withdrawal (Figure 13b).  Although the effect is more pronounced for serum withdrawal 
than lipid withdrawal, the lack of response in cells with oncogenic K-Ras indicates that these 
cells have a disabled response to serum and lipid deprivation.  
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CHAPTER IV 
LIPID WITHDRAWAL CREATES SYNTHETIC LETHALITY FOR 
RAPAMYCIN IN Ras-DRIVEN CANCERS 
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4.1 WITHDRAWAL OF SERUM LIPIDS CREATES SYNTHETIC 
LETHALITY FOR RAPAMYCIN IN CANCERS HARBORING MUTANT 
Ras. 
 
          We previously reported that in the absence of serum, MDA-MB-231, as well as most other 
cancer cells, are killed by rapamycin treatments capable of suppressing phosphorylation of the 
mTORC1 substrate eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) [112, 113] 
(Figure 14a).  In the presence of serum, cells are protected by TGF-β present in serum, which 
prevents apoptosis by inducing G1 cell cycle arrest [113, 118] (Figure 14b).  However, while the 
MDA-MB-231 cells were protected from the apoptotic effect rapamycin by TGF-β alone, these 
cells were not completely healthy and there was significant sub-genomic DNA indicating some 
level of apoptosis [113].  Thus, there was apparently something else in the serum that along with 
TGF-β contributed to survival.  We therefore examined the effect of serum lipids on the effect of 
rapamycin on cell viability of MDA-MB-231, BJ, and MCF7 cells.  As reported previously, in 
the absence of serum, rapamycin (20 µM) induced cleavage of the caspase 3 substrate poly-
ADP-ribose polymerase (PARP) in the MDA-MB-231 cells – indicating apoptotic death (Figure 
15a).  PARP cleavage was not observed in the presence of 10% FBS.  PARP cleavage was not 
observed with rapamycin treatment in the BJ or MCF7 cells in either the presence or absence of 
serum.  Most significantly, if cells were deprived of lipids, by incubating in 10% delipidated 
serum, rapamycin still induced PARP cleavage – indicating that the lack of lipids created a 
synthetic lethal phenotype for rapamycin treatment.  If the FA mix was provided in the absence 
of FBS, rapamycin still induced apoptosis – consistent with our previous observation that TGF-β 
was required for suppressing rapamycin-induced apoptosis in the presence of serum.  If the FA 
mixture was combined with the delipidated serum PARP cleavage was suppressed.  
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           Stimulation of apoptosis, indicated by induction of PARP cleavage in the delipidated 
serum required the high dose of rapamycin (Figure 15b) that causes a complete dissociation of 
mTOR from the mTORC1 companion protein Raptor and suppresses 4E-BP1 phosphorylation 
[112].   
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          We also examined the effect of rapamycin on MDA-MB-231 cells deprived of lipids on 
cell viability/growth using the MTT assay.  The high dose rapamycin reduced cell viability in the 
absence of FBS (Fig. 16a), in delipidated FBS, and in the presence of the FA mixture – but not in 
the presence of delipidated FBS + FA mixture.  The effect of rapamycin on cell viability on 
MCF7 and BJ cells was substantially less than that observed for the MDA-MB-231 cells (Figure 
16a).  The loss of cell viability, like PARP cleavage, required the high dose rapamycin treatment 
(Figure 16b).  Thus, the K-Ras-driven MDA-MB-231 cells are sensitized to rapamycin by 
depriving cells of either serum lipids or growth factors.   
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4.2 SUPRESSION OF MACROPINOCYTOSIS SENSITIZES Ras-DRIVEN 
CANCER CELLS TO RAPAMYCIN  
 
          The sensitivity of Ras-driven cancer cells deprived of serum lipids to rapamycin suggests a 
means to target the many cancers that harbor Ras mutations.  However, ridding the serum of 
lipids in a human would be problematic.  However, it could be possible to block the uptake of 
serum lipids.  Dafna Bar-Sagi and colleagues demonstrated previously that mutant Ras 
stimulates pinocytosis [119].  We therefore examined whether blocking pinocytosis would also 
sensitize the Ras-driven MDA-MB-231 cells to rapamycin.  Pinocytosis is suppressed by 5-(N-
ethyl-N-isopropyl) amiloride (EIPA) [120].  We examined the effect of EIPA on the rapamycin 
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sensitivity of MDA-MB-231, Calu-1, MCF7, and BJ cells in the presence of 10% FBS. EIPA 
treatment made the MDA-MB-231 and Calu-1 cells sensitive to the apoptotic effect of 
rapamycin (Figure 17a), while having no such effect on the MCF7 or BJ cells.  Another indicator 
of apoptotic cell death is the appearance of sub-genomic DNA.  We compared the levels of sub-
genomic DNA in the BJ and MDA-MB-231 cells treated with EIPA and rapamycin. The 
combination of EIPA and rapamycin induced a substantial increase in sub-genomic DNA in the 
MDA-MB-231, but not the BJ cells (Figure 17b, Table 4).  Importantly, EIPA treatment alone 
had no significant effect on viability of cells.  
           We also examined whether EIPA could sensitize the BJ cells expressing activated K-Ras 
cells to rapamycin treatment. The BJ-KRas cells displayed PARP cleavage when treated with the 
combination of EIPA and 20 µM rapamycin (Figure 18).  Thus, EIPA, like lipid deprivation, 
creates a synthetic lethal phenotype for rapamycin in K-Ras-driven cancer cells. 
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4.3 POSSIBLE MECHANISM OF LIPID UPTAKE IN Ras-DRIVEN CELLS 
 
          Fatty acids, which are insoluble in water, associate with either albumin, to create so-called 
plasma free fatty acid (FFA), or are esterified and packaged as lipoprotein complexes together 
with triglycerides, cholesterol and phospholipids, and these complexed structures enable their 
transport in the plasma [121]. There are several pathways that allow uptake of various serum 
lipid species. Cell surface receptors allow uptake of whole lipoprotein complex via clathrin-
depended endocytosis [122]. Alternatively, cells could obtain free fatty acids through work of 
two FA translocases, scavenger receptor A (SR-A) and CD36 via saturable protein-facilitated 
process [123]. Additionally, lipids could be taken up through non-specific macropinocytosis that 
involves engulfing of extracellular material that contains lipid droplets [124, 125]. The relative 
contribution to the uptake by each of the three way is not known. However, when large amounts 
of lipids need to be taken up, lipoprotein receptor, FA translocases and pinocytosis pathways are 
involved in internalization of lipids [126].  
          It had been reported that Ras mutation induces increased ruffling and macropinocytosis in 
cell, and that it leads to increased fluid endocytosis [119, 127]. The functional role of 
macropinocytotic uptake is not fully elucidated, however recent report has shown that increased 
pinocytotic uptake leads to significant internalization of album to support increased need of 
cancer cells for glutamine as anaplerotic source [25].  Here, we hypothesized that increased rate 
of pinocytosis in Ras-driven cells is used as a transport mechanism for their unique metabolic 
need for exogenously supplied FA.  
          To determine whether oncogenic Ras does indeed lead to increased philopodia formation 
in cells in our hands, we compared the amount of philopodia is MDA-MB-231 cells to BJ cells. 
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Live cells were stained with lipid marker, BODYPY 500/510C12, and live images were taken 
using confocal microscope. In the absence of serum stimulation, MDA-MB-231 cells have a 
higher number of philopodia (not shown) comparative to BJ cells. In addition, the observed 
philopodia are highly dynamic (not shown), as described previously: cells internalized 
approximately 25% of their cell volume during the course of active pinocytosis [128]. To 
confirm that increased philopodia formation is indeed due to activated Ras, we transiently 
transfected BJ cells with a plasmid expressing oncogenic K-Ras (K-RasV12G).  The cells 
transfected with the K-RasV12G plasmids had significantly higher amount of philopodia-like 
protrusions compared to the control BJ cells transfected with vector alone (Figure 19). We have 
previously used EIPA as a pinocytotic inhibitor.  Our preliminary observations show that EIPA 
treatment leads to decreased number and to shorter philopodia.  
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5.1 NATURE OF THE FA INFLUENCES mTOR RESPONSE  
 
            It has been reported that dietary lipids stimulate S6K1 phosphorylation in vitro and in 
vivo, and that this effect is independent of amino acid stimulation of mTOR [129]. We have 
recently proposed that PA serves as a sensor of lipid sufficiency to mTOR. Recent reports had 
shown that mTOR is being differentially activated depending of the saturation level of PA 
species. PA species with two saturated palmitates had been shown to inhibit mTORC2 [95], 
while 1-palmitoyl, 2-oleoyl-PA is stimulatory for both mTORC1 and mTORC2 [51, 96]. Thus, 
some degree of desaturation on PA is needed for activation of mTOR.  Given the link between 
oncogenic Ras and sensitivity to lipid withdrawal, we sought to compare responsiveness of 
mTOR substrates in MDA-MB-231 and BJ cells when placed in various lipid conditions. As 
shown in Figure 20, S6K1 phosphorylation was sensitive serum and lipid withdrawal ( 0% serum 
condition) in BJ and to lesser extend  in MDA-MD-231 cells, however lipid withdrawal alone 
has very little effect on phosphorylation level of S6K1 in both cell types. Re-addition of mixture 
of FA stimulated S6K1 phosphorylation in BJ cells slightly, indicating that in normal cells, for 
complete mTORC1 activation, growth factor stimulation is necessary. Lipid withdrawal had a 
more drastic effect on the phosphorylation level of Akt at the mTORC2-dependent site S473. 
Lipid withdrawal led to significant reduction of phosphorylation levels of Akt (S473) in BJ cells 
while having almost no effect on MDA-MB-231 cells (Figure 20). FA re-stimulation led to slight 
increases in phosphorylation level of Akt (S473) in both BJ and MDA-MB-231 cells. 
Importantly, re-stimulation with palmitic acid alone had inhibitory effect on Akt phosphorylation 
in both cell types. This observation suggests that if PA species that feed into mTOR come from 
dietary lipids, then some level of unsaturation is necessary for the activation of the mTOR, 
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consistent with the reported finding that di-palmitoyl PA leads to inhibition of mTORC2 [95]. 
Taken together, these data indicate that Ras-driven cells exhibit lessen responsiveness to lipid 
withdrawal compared to normal cells. These data further support apparent insensitivity of Ras-
driven cells to exogenous lipids due to concurrent increase in PLD activity that supplies mTOR 
with PA to keep metabolic machinery going when lipid resources are scarce.  
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5.2 EIPA TREATMENT LEADS TO DISSOCIATION OF MTORC1 
COMPLEX, FURTHER ENHANCING EFFECT OF RAPAMYCIN  
 
          EIPA treatment in sense mimics lipid withdrawal. However, an unexpected result of EIPA 
treatment is reduced levels of S6K1 phosphorylation and Akt (S473) phosphorylation in MDA-
MB-231 and BJ cells (Figure 21) and other cell lines (data not shown).  
 
         We have previously reported that nano-molar rapamycin concentration disrupts the 
association between mTOR and raptor, and the weakening in mTORC1 structure association was 
sufficient to abolish S6K1 phosphorylation [51, 112]. PA has been shown to stabilize mTOR 
complexes [51], however, the nature of PA lipid moieties influences activation or inhibitory 
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effect on mTOR [51, 95, 96]. Because EIPA mimics lipid withdrawal, we hypothesized that 
EIPA treatment could lead to increased local concentration of inhibitory di-palmitoyl species of 
PA, leading to dissociation of mTOR complexes. We therefore examined the association of 
mTOR and raptor in the presence of EIPA and EIPA/rapamycin combination. MDA-MB-231 
and BJ cells where treated in full serum condition with high dose rapamycin, EIPA or 
combination of both, and relative association level of mTOR with its accessory proteins, raptor 
and rictor, was evaluated. High dose of rapamycin led to partial dissociation of both mTORC1 
and mTORC2 in full serum condition compared to untreated control (Figure 22). Importantly, 
EIPA addition alone was sufficient to induce weakened structure of mTORC1 and mTORC2 
(Figure 22). Moreover, combinatory EIPA/rapamycin treatment led cumulative decrease in the 
association of both mTOR complexes. Taken together, these data support the hypothesis that 
dietary-derived lipids influence mTOR association, and that mTOR complexes are more 
sensitive to rapamycin in absence of lipids is due to initial weakened interaction.  
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5.3 PA SUPPLEMENTATION RESCUES EIPA-INDUCED 
DISACTIVATION OF mTORC1  
 
Mammalian cells could produce palmitic and stearic acid from glucose or glutamine as a carbon 
bone precursor. Palmitic and strearic acid could be desaturated by SCD-1 to form palmitoic and 
oleic acids respectively. However, we have observed expression of oncogenic Ras leads to 
significant decrease of SCD1 expression (Figure 13). EIPA treatment leads to blockage of 
macropinocytotic uptake of FA, and presumably, increasing the concentration of palmitic acid in 
the cells. In order to directly test if association between mTOR complexes is disrupted due to 
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lowered PA concentration or change in structure of PA species when treated with EIPA, we 
examined whether effect could be reversed by addition of PA. As shown in Figure 23, the 
activation of mTORC1 was rescued with concurrent addition of EIPA and palmitoyl-oleyl-PA, 
but not di-palmitoyl-PA.  
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DISCUSSION 
          Over past decade, metabolic alterations in cancer cells have received a substantial amount 
of interest. It had been established that cancer cells undergo a significant amount of metabolic 
alterations, and some of these alterations are similar to those in normal highly proliferative cells 
[19]. However, it is becoming more apparent that many of the metabolic alterations are specific 
to particular oncogenic signaling pathways [22]. Although altered metabolic machinery makes 
cancer cells more efficient at promoting growth when nutrients are supplied at the sufficient 
amounts, the dependency of cancer cells on particular metabolic reprogramming deems cancer 
cells susceptible to disruptions within metabolic network. Thus, the identification of metabolic 
weaknesses of cancer cells create a platform for therapeutic interventions.  
6.1 Ras-DRIVEN CELLS ARE HIGHLY DEPENDENT ON EXOGENOUS 
SUPPLY OF FA  
 
         The data presented here reveal an enhanced requirement for lipids in human cancer cells 
harboring activating Ras mutations.  Depriving these cells of lipids leads to what we would call a 
“replicative cell death” – continued attempts to proliferate in the absence of sufficient nutrients.  
Whereas most cells are capable of synthesizing fatty acids for membrane phospholipids from 
glucose or glutamine [91, 108], the Ras-driven cancer cells apparently have a greater need for 
exogenously supplied lipids.  This unique property of Ras-driven cancer cells is apparently an 
Achilles’ heel for Ras-driven cancer cells in that suppressing mTOR in these cells induces 
apoptosis if the uptake of lipids is suppressed. 
Of significance, two very recent reports have also identified the need for exogenously 
supplied protein as an amino acid supply [25] and for lipids [130] in Ras-transformed cells.   The 
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uptake of albumin served as a source of glutamine for needed for cell growth [25].  We used 
albumin as a carrier for exogenously supplied lipids to promote cell survival and rapamycin 
resistance.  The use of albumin alone did not promote survival by itself (Figure 9) – indicating 
that while Ras-transformed cells depend on scavenged proteins as an amino acid source for cell 
growth, it was the lipids that were critical for survival and resistance to rapamycin.  The lipid 
requirement for exogenous lipids by Ras-transformed cells was dependent on an unsaturated 
fatty acid [130].  Consistent with this, the saturated fatty acid palmitic acid was not able to 
substitute for the mixture of fatty acids used in this study, which consisted with several 
unsaturated fatty acids.  
6.2 ONCOGENIC Ras ALTERS EXPRESSION LEVEL OF SCD1 
 
The dependence of Ras-transformed cells on exogenously supplied nutrients over 
standard de novo synthetic pathways appears to be a Ras-driven program shift.  In response to 
the lack of serum lipids, cells lacking mutant Ras showed a dramatic increase in the level of 
SCD1 (Figure 13).  This is consistent with the recent report from the Rabinowitz and Thompson 
labs where they showed that Ras-transformed cells were resistant to inhibition of SCD1.  
Although they did not look at SCD1 protein levels, their study also demonstrated that SCD1 was 
not important for the growth of Ras-transformed cells.  It is likely that the lack of increased 
SCD1 expression in the Ras-transformed cells is a reflection of the apparent scavenger program 
stimulated by Ras that involves macropinocytosis [119]. 
Our data showed that induction of SCD1 expression was stimulated after 18 hours of 
lipid withdrawal, indicating that levels of SCD1 are modulated at the rate of transcription [131]. 
These data is consistent with previous reports, and promoter region of SCD1 contains a number 
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of transcription factor binding sites [132], including sterol response element-binding protein 
(SREBP). However, the mechanism of regulation of SCD1 expression and modulation of its 
levels are not fully elucidated [133]. Interestingly, one study reported that when levels of SCD1 
are down-regulated, there is concurrent up-regulation of levels of fatty acid transporter CD36 
[134]. In this study we show that Ras-driven cells have an increased rate of pinocytosis that leads 
to higher rate of lipid uptake, to compensate for need for unsaturated fatty acids when SCD1 
levels are low. Thus, we show the correlation between the levels of SCD1 and rate of 
macropinocytotic lipid uptake. 
6.3 LIPID WITHDRAWAL AND RAPAMYCIN CREATES SYNTHETIC 
LETHAL EFFECT ON Ras-DRIVEN CELLS  
 
           One of the greatest challenges of cancer therapy is finding a strategy that would 
specifically target cancer cells while being minimally toxic to the rest of the organism. Metabolic 
reprogramming and metabolic dependencies in cancer cells provides an exceptional platform for 
novel therapeutic approaches.  Here, we shown that cancer cells harboring Ras mutation are 
uniquely sensitive to rapamycin treatment when deprived of lipids. 
The rapamycin sensitivity of Ras-transformed cells deprived of lipids or with suppressed 
macropinocytosis may be a reflection of the impact of lipid deprivation on cell cycle progression.  
We reported previously that in the absence of serum, rapamycin induced apoptosis in the MDA-
MB-231 cells, but in the presence of serum, rapamycin induced a TGF-β-dependent G1 cell 
cycle arrest that protected the cells from apoptosis [113, 135].  However, if cells were 
synchronized in early S-phase, then the cells were killed by rapamycin – even in the presence of 
serum/TGF-β.  These studies indicated that if cells get past the TGF-β-dependent G1 cell cycle 
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checkpoint and enter S-phase, then suppression of mTORC1 activates an apoptotic program.  
Consistent with our previous reports, the increase in sub-genomic DNA observed in Figure 17b 
corresponded with large drops in the percentage of cells in S-phase and G2/M cells relative to the 
drop in G1 cells (Table 2).  While these data are too preliminary to draw any firm conclusions 
about why rapamycin kills K-Ras-driven cancer cells when deprived of lipids, the data are 
consistent with an apoptotic effect on cells that have progressed into S-phase.  It is possible that 
depriving K-Ras-driven cancer cells, which suppresses de novo fatty acid synthesis [130], of 
serum lipids leads to the arrest or slowed progression through S-phase.  Once a cell has entered 
S-phase, the cell has committed to replicating its genome and doubling its mass.  If mTORC1 is 
suppressed in S-phase cells – telling the cell that there are not sufficient raw materials to finish 
the job, then a default apoptotic program is activated rather than try to remedy the situation at 
this phase of the cell cycle.  While there is still much to be learned about the impact of mTORC1 
suppression on cells in S-phase, it is clear that in K-Ras-driven cancer cells, depriving cells of 
lipids, creates a synthetic lethal phenotype for rapamycin treatment that could create therapeutic 
strategies for targeting the large number of human cancers that harbor Ras mutations.  
6.4 DIETARY LIPIDS DISPLAY AN ACTIVATORY EFFECT ON mTOR 
 
          In addition to need for glucose and amino acids as building blocks for macromolecular 
synthesis during cell growth and proliferation, actively dividing cells require exogenous or de 
novo synthesized lipids as precursors for membrane biosynthesis. Although most cancer cells 
display enhanced uptake of the nutrients, glucose and glutamine among most studied, from the 
environment, there is also observed concurrent aberrant response to sufficiency sensing of 
macromolecular precursors as noted with continuous proliferation during stress of nutrient 
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insufficiency. Not surprisingly, PI-3K/mTOR pathway that is responsible for checking of 
nutrient sufficiency in cells is one of the most commonly mutated pathways in cancer [10, 11].    
          mTOR has been implicated as an integrator of nutrient sufficiency and stress in cells and is 
activated by amino acids and glucose. However, cells also require lipids for membrane 
biosynthesis and survival. We have recently proposed that mTOR serves as sensor of lipid 
sufficiency through a lipid metabolite necessary for mTOR stability and activity, PA [56]. Of 
interest, we have previously shown that Ras-driven cancers display an elevated PLD activity in 
response to serum withdrawal, and that the increase in PLD activity is necessary for cell survival 
[77, 111]. Here, we have shown that PLD activity is increased in Ras-driven cells when deprived 
of lipids alone (Figure 8). It could be suggested that the increase in PLD-generated PA might 
temporarily supply mTOR with PA for mTOR activation to keep metabolic machinery running 
in the event of stress of nutritional insufficiency.  
         Here, we set forth to determine the effect of lipid stimulation on downstream targets of 
mTOR in normal and Ras-driven cells. We have observed that oncogenic Ras gives the cells an 
altered responsiveness to various lipid stimuli compared to the response in most normal cells 
(Figure 22). Whereas in normal cell line there is a shutting down of mTORC1 and mTORC2 as 
observed with decreased phosphorylation levels of S6K1 and Akt (S473) when deprived of lipids 
alone, in Ras-driven cell line, MDA-MB-231, there are no observed changes in phosphorylation 
levels of S6K1 and Akt (S473) under the same condition. Taken together, these observations 
could be viewed as a maneuvering act of an oncogene to keep the metabolic machinery going in 
the event of metabolic stress. PLD activity is increased in Ras-driven cell lines in response to 
stress due to lipid withdrawal to feed into mTOR for temporary survival of the cells.  
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6.5 LIPID SENSING BY mTOR 
 
          mTOR is a central sensor of essential nutrients needed for the synthesis of 
macromolecules, and it has been known to respond to amino acids, glucose and energy. Another 
essential nutrient for cell growth and proliferation are lipids. We have recently proposed that PA 
feeds into mTOR as a “check” for the lipid sufficiency [56]. An amiloride, EIPA, that blocks 
pinocytotic lipid uptake, was used to inhibit lipid uptake. In essence, EIPA treatment mimics 
LPAAT blockage. LPAAT which generates PA from dietary lipids, had been shown to activate 
mTOR [74]. Here, we have observed that EIPA treatment blocks S6K1 phosphorylation, 
indicating an indirect inhibition of PA production. Addition of PA was able to rescue the effect 
of EIPA, further supporting PA input into mTOR for its activation. Importantly, addition of 
palmitoyl-oleyl-PA, but not di-palmitoyl-PA was able to rescue mTOR activation when lipid 
uptake was blocked by EIPA treatment.  
6.6 SIGNIFICANCE  
 
          The findings reported here reveal an enhanced need for serum lipids in Ras-driven human 
cancer cells that creates a synthetic lethal phenotype for suppressing mTORC1.  While depriving 
humans of serum lipids is not practical, suppressing uptake of lipids is possible and could be 
exploited therapeutically.  It is speculated that this property displayed by Ras-driven cancer cells 
represents an Achilles’ heel for the large number of human cancers that are driven by activating 
Ras mutations.   
          mTOR has long been known to respond to amino acids, glucose and energy. However, 
lipids are another essential nutrient, and sensing mechanism on sufficiency of lipid precursors is 
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not yet known.  Based on the central position of PA in lipid biosynthesis, and its involvement in 
mTOR regulation, here we show that PA feeds into mTOR as a metabolite for sensing lipid 
precursors. In Ras-driven cells, PLD activity increase due to lipid withdrawal may be a 
mechanism to keep mTOR active during metabolic insufficiency stress.  
6.7 FUTURE DIRECTIONS  
          6.7.1 We have shown that removal of serum lipids or inhibition of lipid uptake through 
general macropinocytosis inhibition increased the susceptibility of Ras-driven cells to 
rapamycin-induced cell death in vitro. Perhaps, the most interesting and clinically significant 
future direction is to confirm these finding in mice model. Amilorides are used since 1967 for 
treatment of cardiac ischemia and hypertentions. EIPA, and amiloride used in this study, blocks 
macropinocytosis and lipid uptake. Thus, suppressing uptake of lipids is possible and could be 
exploited therapeutically, presenting that this property displayed by Ras-driven cancer cells 
represents an Achilles’ heel for the large number of human cancers that are driven by activating 
Ras mutations.   
          6.7.2 We have shown that expression of oncogenic Ras correlates to inhibition of SCD1 
expression. It is known that the activity of SCD1 is regulated at the level of transcription [133], 
however the precise mechanism of the expression is not fully elucidated. The mechanistic basis 
of possible Ras regulation of SCD1 expression is of much interest as well.  
          6.7.3 In this study we used a mixture of lipids which contained saturated and unsaturated 
lipids. It is of our interest to define which lipid species could rescue the lipid dependence of Ras-
expressing tumor cells by supplementing media with a single lipid species (e.g., oleate, 
arachidonate, linoleate and/or linolenate). Additionally, an important question is to by define 
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which lipids are taken up via pinocytosis versus lipid transporters. We could speculate that lipid 
species of various levels of saturation are taken up non-specifically, however, the specificity of 
lipid sensing is acquired at the level of PA that feeds into mTOR.  
         6.7.4 PLD is not the only source of PA that could feed into mTOR. Ras-driven cells display 
an increase in PLD activity when stressed by growth factor and/or lipid withdrawal. Our study 
suggests that Ras-driven cells circumvent cell death initially when deprived of lipids by 
supplying mTOR with PA to keep metabolic machinery running during metabolic stress. 
Whether additional PA-producing enzymes, LPAAT or DGK contribute to cell survival is of 
interest to evaluate. These findings would further connect mTOR to control of lipid sensing 
through enzymes that generate PA. 
         6.7.5 Among other questions that are of general interest, but stand beyond the scope of this 
project, are: 
How is Ras signaling and lipid pinocytosis connected? Does activated Ras “sense” lipid presence 
in the environment? 
Is there a connection between PLD activity increase and inhibition of SCD1 expression?  
Does SCD1 inhibition creates synthetic lethal effect in non-Ras-driven cells? 
Is lipid dependency unique to cells with oncogenic Ras?  
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6.8 HOW IT ALL FITS WITHIN THE CELL 
 
           Perhaps, the most interesting part of the finding that there is a difference on how mTOR 
within the cells “senses” various sub-forms of phosphatidic acid, taken that they indeed are able 
to differentiate those lipid moieties.  
           If we start by looking at the close up view of PA binding to FBR domain of mTOR and 
then look at the how FRB domain fits within the total structure of mTOR complexes, it becomes 
clear that electrostatic interaction between lipid and protein potentially has a great effect on the 
mTOR complex formation as a whole.  
            From the crystal structure of mTOR [68], it had been revealed that phosphate group of 
PA binds to a positively charged patch formed by the side chain of R2109. Of a note, R2109 had 
been widely conserved throughout many species [56]. From the interaction of acyl chains of PA 
with FRB domain of mTOR, it is evident that acyl chains with unsaturated residues would bind 
tighter to the protein surface, considering that the surface has a bend shape at the site of PA 
binding. It is possible that PA with di-saturated acyl groups binds to mTOR and distorts its 
structure by increasing the volume of FRB domain and making it an unfavorable for mediator 
proteins to bind.  
          If we look at the mTOR crystal structure as a whole, the inhibitory effect of “swelled up” 
FRB domain becomes more obvious. It appears to be that FRB domain forms a cap on the top of 
the kinase domain [136]. FRB domain that forms a complex with either FKBP12-rapamycin or 
with rigid di-saturated PA species could occupy an additional space, making the cap and the gap 
for downstream targets two small for the interaction with kinase domain.  
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          However, how do mTOR and PLD and PA fit together within the real estate of the cell? It 
had been shown that PLD 2 localizes almost exclusively at the plasma membrane, while PLD1 is 
found throughout the cell, but primarily in perinuclear, Golgi, and heavy membrane fractions 
[137]. mTOR had been shown to be localized to the plasma membrane, lysosomes, 
mitochondria, cytoplasm, peroxisomes, and nucleus [138]. Hence, mTOR and PLD potentially 
co-localize. The interaction between the phospahtidic acid and mTOR presumably occurs at the 
plasma membrane, which limits FRB domain accessibility to one of the acyl groups of PA[68]. 
However, membrane interaction could also mean that the regulation of mTOR by PA occurs via 
targeted localization of the active complex.  
         mTOR localization lies vis-à-vis to its activation, and, perhaps, phosphatidic acid is the 
molecular zip-code on where mTOR decides to dock and activate.  
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